Abstract
Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents. We reviewed the medical records of sequential patients with MBC who presented to our phase I clinic between September 2004 and May 2008 to assess baseline patient characteristics, overall survival (OS), and clinical benefit. A total of 92 patients were identified, with a median age of 53 years (range, 28-83 years). The median number of previous therapies was 5 (range, 1-16 therapies). Of 92 patients, 78 were eligible for and offered > or = 1 phase I clinical trial. With a median follow-up of 7.4 months, the median OS was 6.7 months (95% CI, 5.2-9.7). In multivariate analysis, independent factors predicting shorter survival were > or = 10 previous treatments (vs. < 10 previous treatments; hazard ratio [HR], 3.27; 95% CI, 1.37-7.81; P = .008), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2/3 (vs. 0/1; HR, 2.92; 95% CI, 1.28-6.66; P = .01), and albumin level < 3.5 g/dL (vs. > 3.5 g/dL; HR, 2.88; 95% CI, 1.41-5.89; P = .004). Patients with locally advanced or metastatic brea...Continue Reading
References
Nov 7, 1990·Journal of the National Cancer Institute·R J CoatesR L Brown
Jan 9, 1987·Science·D J SlamonW L McGuire
Oct 1, 1994·Cancer·L JanischM J Ratain
Jun 9, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M PaesmansJ Klastersky
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J AlexandreF Goldwasser
Mar 5, 2004·Breast Cancer Research and Treatment·Mei WuSofia D Merajver
Nov 4, 2004·JAMA : the Journal of the American Medical Association·Thomas G RobertsJeffrey W Clark
Nov 5, 2004·Cancer·Behnam EbrahimiRazelle Kurzrock
Mar 5, 2005·The New England Journal of Medicine·Elizabeth HorstmannChristine Grady
Mar 5, 2005·The New England Journal of Medicine·Razelle Kurzrock, Robert S Benjamin
May 25, 2006·Clinical Pharmacokinetics·Kellie A CharlesStephen J Clarke
Sep 13, 2007·Cancer·David S HongRazelle Kurzrock
Dec 11, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Craig Jordan
Dec 25, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rohini SharmaHani Gabra
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maggie C U CheangTorsten O Nielsen
Jun 11, 2008·Breast Cancer Research and Treatment·Rebecca DentSteven A Narod
Jun 14, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hendrik-Tobias ArkenauStan Kaye
Dec 11, 2008·Journal of the National Cancer Institute·K Robin YabroffEric J Feuer
Jan 24, 2009·Cancer·Jennifer WhelerRazelle Kurzrock
Citations
Feb 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M SchmidtM Schuler
Aug 18, 2016·Breast Cancer Research and Treatment·Fanny Le DuNaoto T Ueno
Jul 29, 2010·British Journal of Cancer·A T BrunettoC Swanton
Jul 23, 2020·Cancer·Bradley R CorrJennifer R Diamond
May 9, 2014·Oncotarget·Jennifer J WhelerRazelle Kurzrock
Jul 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·A SchwandtS P Ivy
Sep 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M SchmidtM Schuler